Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis

References

• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12(1):9-22
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Gonzalez- Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009;27(13):2278-87
   PubMed Web of Science ®Google Scholar
• Peterson ME. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Support Care Cancer 2013;21(8):2341-9
   PubMed Web of Science ®Google Scholar
• Ierano C, Santagata S, Napolitano M, et al. CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells. Cell Death Dis 2014;5(7):e1310
   PubMed Web of Science ®Google Scholar
• Grimaldi A, Balestrieri ML, D’Onofrio N, et al. The synergistic effect of everolimus and chloroquine on endothelial cell number reduction is paralleled by increased apoptosis and reduced autophagy occurrence. PLoS One 2013;8(11):e79658
   Google Scholar
• Panzuto F, Rinzivillo M, Fazio N, et al. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist 2014;19(9):966-74
   PubMed Web of Science ®Google Scholar
• Faggiano A, Ramundo V, Dicitore A, et al. Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. J Cell Mol Med 2012;16(7):1563-72
   Google Scholar
• Yardley DA. Adverse Event Management of mTOR Inhibitors during treatment of hormone receptor–positive advanced breast cancer: considerations for oncologists. Clin Breast Cancer 2014;14(5):297-308
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis. Expert Rev Anticancer Ther 2014;14(12):1529-36
   PubMed Web of Science ®Google Scholar
• Facchini G, Perri F, Caraglia M, et al. New treatment approaches in renal cell carcinoma. Anticancer Drugs 2009;20(10):893-900
   PubMedGoogle Scholar
• Howell D, Keller–Olaman S, Oliver TK, et al. A pan-Canadian practice guideline and algorithm: screening, assessment, and supportive care of adults with cancer-related fatigue. Current Oncology 2013;20(3):e233
   Google Scholar
• Afinitor [Everolimus] tablets for mucocutaneous administration [summary of product characteristics] Stein, Switzerland: Novartis Pharma AG; 2012
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62(10):1006-12
   PubMed Web of Science ®Google Scholar
• National cancer institute. common toxicity criteria. Available from: http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf
   Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12
   PubMedGoogle Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-88
   PubMedGoogle Scholar
• Bower JE, Ganz PA, Desmond KA, et al. Fatigue in breast cancer survivors: occurrence, correlates and impact on quality of life. J Clin Oncol 2000;18:743-53
   PubMed Web of Science ®Google Scholar
• Servaes P, Verhagen S, Bleijenberg G. Determinants of chronic fatigue in disease-free breast cancer patients: a cross-sectional study. Ann Oncol 2002;13:589-98
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol 2014;32(14):1412-18
   PubMed Web of Science ®Google Scholar
• NCCN clinical practice guideline in oncology. cancer-related fatigue. Version 1. 2014. Available from: www.nccn.org/professionals/physician_gls/f_guidelines.asp [Last accessed 17 October 2014]
   Google Scholar
• NCCN clinical practice guideline in oncology. survivorship. Version 1. 2014. Available from: www.nccn.org/professionals/physician_gls/f_guidelines.asp [Last accessed 17 October 2014]
   Google Scholar
• Bower JE, Bak K, Berger A, et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an american society of clinical oncology clinical practice guideline adaptation. J Clin Oncol 2014;32(17):1840-50
   PubMed Web of Science ®Google Scholar
• Puetz TW, Herring MP. Differential effects of exercise on cancer-related fatigue during and following treatment: a meta-analysis. Am J Prev Med 2012;43(2):e1-e24
   PubMed Web of Science ®Google Scholar
• Duijts SF, Faber MM, Oldenburg HS, et al. Effectiveness of behavioral techniques and physical exercise on psychosocial functioning and health-related quality of life in breast cancer patients and survivors – a meta-analysis. Psychooncology 2011;20(2):115-26
   PubMed Web of Science ®Google Scholar
• Minton O, Richardson A, Sharpe M, et al. Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev 2010;7:CD006704
   Google Scholar
• Fife K, Spathis A, Dutton S, et al. A multicenter, randomized, double-blind, placebo-controlled trial of modafinil for lung cancer-related fatigue: dose response and patient satisfaction data. J Clin Oncol 2013(Suppl 15):abstract 9503
   Google Scholar
• Peng L, Zhou Y, Ye X, Zhao Q. Treatment-related fatigue with everolimus and temsirolimus in patients with cancer – a meta-analysis of clinical trials. Tumor Biol 2014. [Epub ahead of print]
   Google Scholar
• Santoni M, Conti A, Massari F, et al. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. Int J Cancer 2014;136(1):1-10
   PubMed Web of Science ®Google Scholar
• Münch A, Müller L, Koska M, et al. A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study. Urol Oncol 2014;32(3):362-70
   PubMedGoogle Scholar
• Huober J, Fasching PA, Hanusch C, et al. Neoadjuvant chemotherapy with paclitaxel and Everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide [EC] ± bevacizumab - results of the randomisedGeparQuinto study [GBG 44]. Eur J Cancer 2013;49(10):2284-93
   PubMed Web of Science ®Google Scholar
• Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of Everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex [EXIST-1]: a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013;381(9861):125-32
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Ajani JA, Bai YX, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 2013;31(31):3935-43
   PubMed Web of Science ®Google Scholar
• Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis [EXIST-2]: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013;381(9869):817-24
   PubMed Web of Science ®Google Scholar
• Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of Everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012;30(22):2718-24
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366(6):520-9
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome [RADIANT-2]: a randomised, placebo-controlled, phase 3 study. Lancet 2011;378(9808):2005-12
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):514-23
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of Everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010;116(18):4256-65
   PubMed Web of Science ®Google Scholar
• Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant Everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27(16):2630-7
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 Randomized Clinical Trial. JAMA 2014;312(1):57-67
   PubMed Web of Science ®Google Scholar
• André F, O’Regan R, Ozguroglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer [BOLERO-3]: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014;15(6):580-91
   PubMed Web of Science ®Google Scholar
• Maass N, Harbeck N, Mundhenke C, et al. Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. J Cancer Res Clin Oncol 2013;139(12):2047-56
   PubMed Web of Science ®Google Scholar
• Wolff AC, Lazar AA, Bondarenko I, et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013;31(2):195-202
   PubMed Web of Science ®Google Scholar
• Rini BI, Bellmunt J, Clancy J, et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 2014;32(8):752-9
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27(23):3822-9
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81
   PubMed Web of Science ®Google Scholar
• Demetri GD, Chawla SP, Ray-Coquard I, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol 2013;31(19):2485-92
   PubMed Web of Science ®Google Scholar